1. Home
  2. ABUS vs MTA Comparison

ABUS vs MTA Comparison

Compare ABUS & MTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.13

Market Cap

929.6M

Sector

Health Care

ML Signal

HOLD

Logo Metalla Royalty & Streaming Ltd.

MTA

Metalla Royalty & Streaming Ltd.

HOLD

Current Price

$6.82

Market Cap

766.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABUS
MTA
Founded
2005
1983
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
929.6M
766.4M
IPO Year
2008
2017

Fundamental Metrics

Financial Performance
Metric
ABUS
MTA
Price
$4.13
$6.82
Analyst Decision
Strong Buy
Hold
Analyst Count
1
1
Target Price
$5.00
$9.00
AVG Volume (30 Days)
1.6M
427.8K
Earning Date
05-13-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
55.26
N/A
EPS
N/A
N/A
Revenue
$14,083,000.00
N/A
Revenue This Year
N/A
$81.63
Revenue Next Year
$239.71
$62.44
P/E Ratio
N/A
N/A
Revenue Growth
128.21
N/A
52 Week Low
$3.04
$2.83
52 Week High
$5.10
$9.25

Technical Indicators

Market Signals
Indicator
ABUS
MTA
Relative Strength Index (RSI) 40.44 46.15
Support Level $3.41 $6.48
Resistance Level $4.71 $7.21
Average True Range (ATR) 0.20 0.32
MACD -0.03 0.05
Stochastic Oscillator 13.57 45.39

Price Performance

Historical Comparison
ABUS
MTA

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About MTA Metalla Royalty & Streaming Ltd.

Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.

Share on Social Networks: